A Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rDNA Origin) Injection] Administered Daily to Naïve Growth Hormone-Deficient Children (iSTUDY)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Genentech
- 13 Mar 2017 Planned End Date changed from 1 Jan 2018 to 6 Nov 2017.
- 13 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Oct 2017.
- 13 Mar 2017 Status changed from recruiting to active, no longer recruiting.